Xilio Therapeutics Announces New Data for XTX601

Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2, at the American Association for Cancer Research Annual Meeting, taking place from April 17-22 in San Diego, California. "The data to be presented at AACR underscore the significant potential of our clinically-validated masking technology to address the central challenge that has limited the advancement of T cell engagers in solid tumors - namely, the inability to achieve meaningful anti-tumor activity without inducing severe systemic toxicities," said Uli Bialucha, Chief Scientific Officer of Xilio Therapeutics. "XTX601 has demonstrated a promising preclinical profile, including potent tumor cell killing across multiple CLDN18.2-expressing tumor models and a favorable tolerability profile in non-human primates, supporting its potential to achieve a wide therapeutic index. Importantly, our modular architecture for masked T cell engagers provides flexibility to rapidly evaluate multiple designs in parallel, including masking of the CLDN18.2 binding domain and/or the addition of a co-stimulatory domain, which enables us to seek to optimize the molecule for the best possible clinical profile."